PRL and pituitary tumor: The evidence does not support the commonly held view that dopamine agonists, which also suppress the secretion of prolactin, are more effective in patients with hyperprolactinemia (who may harbor mixed GH- and prolactin-secreting pituitary tumors) [25, 26].